ICER Panel Agrees Aduhelm Is Overpriced, Has No Clinical Benefit

An expert panel convened by the Institute for Clinical and Economic Review unanimously agreed with ICER Thursday (July 15) that the newly approved Alzheimer’s drug Aduhelm is not worth the $56,000 list price set by manufacturer Biogen and has no net clinical benefit, coming as CMS launches a nine-month effort to decide whether to cover the drug and as some insurers and providers have already opted not to cover or prescribe the drug. Biogen has estimated that somewhere between 1...